Ori Biotech Ltd., a company involved in cell and gene therapy (CGT) manufacturing technology, reported new additions to is executive team to support the commercial launch of its platform and the status of enrollment into their Lightspeed Early Access Program (LEAP).

The company has appointed Gillian Bonthron chief financial officer, and John Machulski as chief operating officer.

Bonthron joins Ori with expertise in transactional finance, financial strategy, and leadership within health technology, most recently at Healx and Perspectum. She has worked globally in senior finance and consulting roles.

Machulski joins Ori from Catalent, where he had operational experience and leadership roles at Lonza, GE Life Sciences (now Cytiva), Sanofi, Pfizer, and J&J.

Thomas Heathman has been promoted to chief commercial officer and will lead the upcoming commercial launch of Ori’s cell therapy manufacturing platform. 

The following industry experts have been added to Ori’s strategic advisory board: Jim Faulkner, chief technology officer at Ascidian Therapeutics and former senior vice president, product delivery at Autolus; Matthew Hewitt vice president, technical officer CGT & biologics at Charles River;  Maik Jornitz former CEI G-Con board member Sunflower Therapeutics, DIANT Pharma and, Bruce Thompson, CEO at Kincell.